GYRE vs RMD · rev $53.5M vs P/E 29, rev $5.65B
Gyre Therapeutics Inc. (GYRE) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Gyre Therapeutics Inc. (GYRE) is a biotechnology company listed on NASDAQ.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported GYRE revenue for 2026-06-30 was $53.5M. Net income was -$32.8M. GYRE currently screens at market cap $589.9M.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
GYRE currently screens at market cap $589.9M. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the GYRE and RMD stock pages for the full models.
Not investment advice.